This Canadian Stock Should Be Avoided Like the Plague Right Now

Here’s why long-term investors may want to simply avoid Cineplex (TSX:CGX) stock like the plague, even if it looks dirt cheap.

| More on:
Caution, careful

Image source: Getty Images

After the record-breaking box office collections of Barbenheimer, investors may think that the Cineplex (TSX:CGX) story may be back on track. But the reality is just the contrary. Even though the company posted growth in its second-quarter (Q2) 2023 quarterly report, it lacks the value that can facilitate long-term returns to investors.

Why? Here are just a few reasons.

Five-year stock price performance of -71%  

At the time of writing, Cineplex stock is down a whopping 71% over the past five years. Notably, this comes despite the stock remaining flat on a year-to-date basis, bolstered by the aforementioned strong box office numbers seen this past quarter.

Despite a return to profitability of late, Cineplex is a company that remains heavily under the microscope of long-term investors. This isn’t the cash flow-producing machine it was five to 10 years ago. Indeed, the cinema business is one with structural headwinds that have continued to manifest themselves in lower customer traffic numbers in recent years.

Competition commissioner sticks to its guns

In late July, Canada’s competition commissioner announced plans to hold its ground on the claim that Cineplex is using deceptive marketing techniques. Responses filed to the tribunal indicated that the Canadian multiplex giant mischaracterized its ticket-purchasing procedures. The claims were essentially that individuals couldn’t book tickets at prices displayed on the website due to additional online booking fees.

While this may be common practice, this is just one of the issues Cineplex is dealing with right now. Consumers have other options (mainly in the form of streaming), and phantom fees and other inconveniences may only serve the company poorly over the long term. Thus, whether Cineplex wins its dispute with the competition commissioner doesn’t really matter — these allegations are indicative of various systemic problems in this sector.

Cineplex’s declining financial health

Cineplex’s financial health took a hit from the pandemic. All investors know that.

However, we’re long past the days of social distancing, mask wearing, and stay-at-home orders. Canadians are able (and for the most part willing) to be jammed back into uncomfortable seating for three hours at a time in an enclosed room.

The thing is, it appears consumers simply don’t want to. Cineplex’s earnings growth rate over the past year was a dismal -16% compared to the entertainment industry, which grew 12.1% over that period. The company’s heavy debt load of $838.4 million remains a thorn in the side of investors, considering its total liabilities ($2.3 billion) are currently greater than its total assets ($2.23 billion).

Bottom line

Cineplex is an intriguing turnaround story for some, with a few interesting catalysts that may entice certain speculators to take a position. However, in my view, long-term investors shouldn’t get sucked into owning this stock here, no matter how cheap it looks.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool recommends Cineplex. The Motley Fool has a disclosure policy.

More on Investing

Canada national flag waving in wind on clear day
Tech Stocks

Trump Trade: Canadian Stocks to Watch

With Trump returning to the presidency, there are some sectors that could boom in Canada, and others to watch. But…

Read more »

A train passes Morant's curve in Banff National Park in the Canadian Rockies.
Investing

Is Canadian National Railway Worth Buying for its 2.2% Dividend Yield?

Let's dive into whether Canadian National Railway (TSX:CNR) is a top buy for long-term investors at this point in the…

Read more »

nuclear power plant
Energy Stocks

Is Cameco Stock Still a Buy?

Cameco stock recently reported earnings that showed the Westinghouse investment is creating some major costs. But that could change.

Read more »

cloud computing
Dividend Stocks

Insurance Showdown: Better Buy, Great-West Life or Manulife Stock?

GWO stock and MFC stock are two of the top names in insurance, but which holds the better outlook?

Read more »

analyze data
Dividend Stocks

Here’s Why the Average TFSA for Canadians Aged 41 Isn’t Enough

The average TFSA simply isn't enough for most Canadians in their early 40s. Here's how to catch up.

Read more »

A plant grows from coins.
Dividend Stocks

The Smartest Dividend-Growth Stocks to Buy With $1,000 Right Now

New dividend-growth investors should consider CN Rail (TSX:CNR) stock and another top play if they're looking to build wealth over…

Read more »

concept of real estate evaluation
Dividend Stocks

How to Earn a TFSA Paycheque Every Month and Pay No Taxes on It

Canadian REITs can turn your TFSA into a monthly paycheque machine for life. Here's how Morguard North American Residential REIT…

Read more »

Start line on the highway
Investing

2 No-Brainer Growth Stocks to Buy Now With $5,000 and Hold Long Term

Market conditions today are ideal for growth investing, and two rising stocks are no-brainer buys in November.

Read more »